AXL and melanoma: The role of MITF in melanoma is controversial as low MITF/AXL ratio has been related to poor predictive response to targeted therapy in melanoma (Muller et al, 2014), while others have reported the involvement of MITF in unresponsiveness to MAPKi and melanoma progression (Wellbrock & Arozarena, 2015; Smith et al, 2016).